Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03668340 · ClinicalTrials.gov registry record · Phase 2
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
A Phase 2 study of Uterine Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT03668340: Active Phase 2 study of Uterine Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03668340 is a Phase 2 study of Uterine Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 49 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03668340, a Phase 2 study of Uterine Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775
Primary Outcome
Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) \[Eur J Ca 45:228-247, 2009\]
Conditions Studied
Interventions
- DRUG AZD1775
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
What the registry record for NCT03668340 still lists
NCT03668340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD1775 is the first listed.
NCT03668340 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03668340 about?
NCT03668340 is a clinical study titled "AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma". This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775
What is the current status of trial NCT03668340?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-10-22. Estimated completion is 2027-07-01.
What conditions does trial NCT03668340 study?
This clinical trial studies the following conditions: Uterine Cancer.
What interventions are being tested in trial NCT03668340?
The interventions under investigation include: AZD1775 (DRUG).
Who is sponsoring clinical trial NCT03668340?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03668340 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03668340's enrollment target sits among peer trials
49 12th of 27 higher than 16 of 27 other Uterine Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uterine Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
[18F]FES PET/.CT in Uterine Cancer
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Image-Guided Gynecologic Brachytherapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI